Could a simple drug tweak metabolism in obesity?

NCT ID NCT05028803

Completed Knowledge-focused Sponsor: University of Nottingham Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether sodium phenylbutyrate can lower levels of branched chain amino acids (BCAAs) in the blood of obese and prediabetic men. High BCAAs are linked to insulin resistance and type 2 diabetes. Researchers also looked at how the drug affects blood sugar, insulin sensitivity, and muscle protein building. The trial involved 8 men and was completed at the University of Nottingham.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sodium phenylbutyrate
What this could lead to: If successful, this could point toward a way to improve metabolic health in people with obesity or prediabetes by lowering certain amino acids.
What could go wrong: This is a very small, early-stage study with only 8 participants, so results may not apply to the general population. The drug may not meaningfully affect blood sugar or insulin sensitivity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESE NON DIABETIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

obesity disorder prediabetes syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESE NON DIABETIC

Contacts and locations

Locations

University of Nottingham

Derby, Derbyshire, DE22 3NE, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.